Chardan Capital Issues Pessimistic Forecast for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price
4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its target price reduced by Chardan Capital from $30.00 to $28.00 in a research report released on Tuesday,Benzinga reports. They currently have a buy rating on the stock. Several other equities analysts have also issued reports on the stock. Royal Bank of Canada cut their price target […]
4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its target price reduced by Chardan Capital from $30.00 to $28.00 in a research report released on Tuesday,Benzinga reports. They currently have a buy rating on the stock. Several other equities analysts have also issued reports on the stock. Royal Bank of Canada cut their price target […]
